News releases

New Unitaid-led dashboard aims to accelerate market access for new malaria innovations

A first-of-its-kind product dashboard brings together critical data on the development, introduction and scale-up of malaria innovations, helping countries and partners identify access barriers, coordinate efforts and accelerate the availability of new treatment options.

© Unitaid

As biological threats, such as antimalarial drug resistance, threaten gains made against malaria, accelerating access to innovations is becoming increasingly urgent. Yet, bringing new products to market is a complex process that involves regulatory approvals and coordination across numerous organizations. Until now, information on where new tools stand along the product introduction pathway has been fragmented and often times opaque, making it difficult for countries and partners to track progress and timelines, identify bottlenecks, and coordinate efforts to accelerate access.

The Malaria Product Launch Dashboard, developed by Unitaid and funded by the Gates Foundation, with inputs from across the malaria community, is an innovative online platform created to bring clarity and transparency to the product introduction process Designed as a public good, it brings together essential information across the product launch journey from research and development to country introduction, giving countries, funders and implementing partners a shared view of where products stand and what needs to happen next.

New lifesaving products undertake a long journey before they are recommended, WHO prequalified and, eventually, reach communities in need. We have set out to evaluate whether a dashboard that outlines progress, challenges and opportunities will provide the malaria community with a tool that helps to accelerate the introduction of new treatments by providing information that allows for enhanced coordination and collaboration to overcome barriers along the pathway.

Jan Kolaczinski

Senior Technical Manager for malaria at Unitaid

The dashboard will initially focus on four antimalarial medicines at various stages of development and introduction, which form the backbone of multiple first-line therapy to mitigate antimalarial drug resistance. This will help test an approach that could eventually be applied more widely to other malaria innovations.

National malaria programs, product developers, regulators, funders and implementing partners contributed to the development of the dashboard, and have helped ensure it reflects the needs of those working to introduce new treatments.

Hosted on the RBM Partnership to End Malaria website, the dashboard is part of a larger Unitaid-led initiative to increase transparency across malaria product introduction and accelerate market entry.